U.S. flag

An official website of the United States government

NM_000152.5(GAA):c.2479C>T (p.Gln827Ter) AND not provided

Germline classification:
Pathogenic (2 submissions)
Last evaluated:
May 10, 2023
Review status:
2 stars out of maximum of 4 stars
criteria provided, multiple submitters, no conflicts
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV001091539.24

Allele description [Variation Report for NM_000152.5(GAA):c.2479C>T (p.Gln827Ter)]

NM_000152.5(GAA):c.2479C>T (p.Gln827Ter)

Gene:
GAA:alpha glucosidase [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
17q25.3
Genomic location:
Preferred name:
NM_000152.5(GAA):c.2479C>T (p.Gln827Ter)
HGVS:
  • NC_000017.11:g.80117747C>T
  • NG_009822.1:g.21192C>T
  • NM_000152.5:c.2479C>TMANE SELECT
  • NM_001079803.3:c.2479C>T
  • NM_001079804.3:c.2479C>T
  • NP_000143.2:p.Gln827Ter
  • NP_001073271.1:p.Gln827Ter
  • NP_001073272.1:p.Gln827Ter
  • LRG_673:g.21192C>T
  • NC_000017.10:g.78091546C>T
Protein change:
Q827*
Links:
dbSNP: rs2039389744
NCBI 1000 Genomes Browser:
rs2039389744
Molecular consequence:
  • NM_000152.5:c.2479C>T - nonsense - [Sequence Ontology: SO:0001587]
  • NM_001079803.3:c.2479C>T - nonsense - [Sequence Ontology: SO:0001587]
  • NM_001079804.3:c.2479C>T - nonsense - [Sequence Ontology: SO:0001587]
Observations:
3

Condition(s)

Synonyms:
none provided
Identifiers:
MedGen: C3661900

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV001247658CeGaT Center for Human Genetics Tuebingen
criteria provided, single submitter

(CeGaT Center For Human Genetics Tuebingen Variant Classification Criteria Version 2)
Pathogenic
(Jun 1, 2019)
germlineclinical testing

Citation Link,

SCV004236231Revvity Omics, Revvity
criteria provided, single submitter

(ACMG Guidelines, 2015)
Pathogenic
(May 10, 2023)
germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineyes3not providednot providednot providednot providedclinical testing
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.

Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL; ACMG Laboratory Quality Assurance Committee..

Genet Med. 2015 May;17(5):405-24. doi: 10.1038/gim.2015.30. Epub 2015 Mar 5.

PubMed [citation]
PMID:
25741868
PMCID:
PMC4544753

Details of each submission

From CeGaT Center for Human Genetics Tuebingen, SCV001247658.26

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not provided3not providednot providedclinical testingnot provided
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineyesnot providednot providednot provided3not providednot providednot provided

From Revvity Omics, Revvity, SCV004236231.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Oct 20, 2024